{"pmid":32448041,"title":"Covid-19 induced superimposed bacterial infection.","text":["Covid-19 induced superimposed bacterial infection.","Viral respiratory infections are very common and they are frequently eliminated from the body without any detrimental consequences. Secondary serious bacterial infection has been an apprehension expressed by health care providers, and this fear has been exacerbated in the era of Covid-19. Several published studies have shown an association between Covid-19 illness and secondary bacterial infection. However, the proposed mechanism by which a virus can develop a secondary bacterial infection is not well delineated. The aim of this commentary is to update the current evidence of the risk of bacterial infection in patients with Covid-19. We present several clinical studies related to the topic as well as a brief review of the potential pathophysiology of secondary infections that could present with Covid-19.","J Biomol Struct Dyn","Hendaus, Mohamed A","Jomha, Fatima A","32448041"],"abstract":["Viral respiratory infections are very common and they are frequently eliminated from the body without any detrimental consequences. Secondary serious bacterial infection has been an apprehension expressed by health care providers, and this fear has been exacerbated in the era of Covid-19. Several published studies have shown an association between Covid-19 illness and secondary bacterial infection. However, the proposed mechanism by which a virus can develop a secondary bacterial infection is not well delineated. The aim of this commentary is to update the current evidence of the risk of bacterial infection in patients with Covid-19. We present several clinical studies related to the topic as well as a brief review of the potential pathophysiology of secondary infections that could present with Covid-19."],"journal":"J Biomol Struct Dyn","authors":["Hendaus, Mohamed A","Jomha, Fatima A"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32448041","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/07391102.2020.1772110","keywords":["covid-19","pathogenesis","secondary bacterial infection","studies"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667785213977034752,"score":9.490897,"similar":[{"pmid":32393593,"title":"Recognition and management of respiratory coinfection and secondary bacterial pneumonia in patients with COVID-19.","text":["Recognition and management of respiratory coinfection and secondary bacterial pneumonia in patients with COVID-19.","The pathophysiology of COVID-19 is not fully known. Respiratory infection caused by more than one viral pathogen (viral co-infection) or both viral and bacterial pathogens (combined viral and bacterial pneumonia) have been described. Secondary bacterial pneumonia can follow the initial phase of viral respiratory infection or occur during the recovery phase. No obvious pattern or guidelines exist for viral coinfection, combined viral and bacterial pneumonia, or secondary bacterial pneumonia in the context of SARS-CoV-2. Based on existing clinical data and experience with similar viruses such as influenza and SARS-CoV, the management approach in the context of COVID-19 should, ideally, take into consideration the overall presentation as well as the trajectory of illness.","Cleve Clin J Med","Wu, Chao-Ping","Adhi, Fatima","Highland, Kristin","32393593"],"abstract":["The pathophysiology of COVID-19 is not fully known. Respiratory infection caused by more than one viral pathogen (viral co-infection) or both viral and bacterial pathogens (combined viral and bacterial pneumonia) have been described. Secondary bacterial pneumonia can follow the initial phase of viral respiratory infection or occur during the recovery phase. No obvious pattern or guidelines exist for viral coinfection, combined viral and bacterial pneumonia, or secondary bacterial pneumonia in the context of SARS-CoV-2. Based on existing clinical data and experience with similar viruses such as influenza and SARS-CoV, the management approach in the context of COVID-19 should, ideally, take into consideration the overall presentation as well as the trajectory of illness."],"journal":"Cleve Clin J Med","authors":["Wu, Chao-Ping","Adhi, Fatima","Highland, Kristin"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32393593","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3949/ccjm.87a.ccc015","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666627827811745793,"score":246.96107},{"pmid":32358954,"pmcid":"PMC7197596","title":"Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing.","text":["Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing.","BACKGROUND: To explore and describe the current literature surrounding bacterial/fungal co-infection in patients with coronavirus infection. METHODS: MEDLINE, EMBASE, and Web of Science were searched using broad based search criteria relating to coronavirus and bacterial co-infection. Articles presenting clinical data for patients with coronavirus infection (defined as SARS-1, MERS, SARS-COV-2, and other coronavirus) and bacterial/fungal co-infection reported in English, Mandarin, or Italian were included. Data describing bacterial/fungal co-infections, treatments, and outcomes were extracted. Secondary analysis of studies reporting antimicrobial prescribing in SARS-COV-2 even in the absence of co-infection was performed. RESULTS: 1007 abstracts were identified. Eighteen full texts reported bacterial/fungal co-infection were included. Most studies did not identify or report bacterial/fungal coinfection (85/140;61%). 9/18 (50%) studies reported on COVID-19, 5/18 (28%) SARS-1, 1/18 (6%) MERS, and 3/18 (17%) other coronavirus.For COVID-19, 62/806 (8%) patients were reported as experiencing bacterial/fungal co-infection during hospital admission. Secondary analysis demonstrated wide use of broad-spectrum antibacterials, despite a paucity of evidence for bacterial coinfection. On secondary analysis, 1450/2010 (72%) of patients reported received antimicrobial therapy. No antimicrobial stewardship interventions were described.For non-COVID-19 cases bacterial/fungal co-infection was reported in 89/815 (11%) of patients. Broad-spectrum antibiotic use was reported. CONCLUSIONS: Despite frequent prescription of broad-spectrum empirical antimicrobials in patients with coronavirus associated respiratory infections, there is a paucity of data to support the association with respiratory bacterial/fungal co-infection. Generation of prospective evidence to support development of antimicrobial policy and appropriate stewardship interventions specific for the COVID-19 pandemic are urgently required.","Clin Infect Dis","Rawson, Timothy M","Moore, Luke S P","Zhu, Nina","Ranganathan, Nishanthy","Skolimowska, Keira","Gilchrist, Mark","Satta, Giovanni","Cooke, Graham","Holmes, Alison","32358954"],"abstract":["BACKGROUND: To explore and describe the current literature surrounding bacterial/fungal co-infection in patients with coronavirus infection. METHODS: MEDLINE, EMBASE, and Web of Science were searched using broad based search criteria relating to coronavirus and bacterial co-infection. Articles presenting clinical data for patients with coronavirus infection (defined as SARS-1, MERS, SARS-COV-2, and other coronavirus) and bacterial/fungal co-infection reported in English, Mandarin, or Italian were included. Data describing bacterial/fungal co-infections, treatments, and outcomes were extracted. Secondary analysis of studies reporting antimicrobial prescribing in SARS-COV-2 even in the absence of co-infection was performed. RESULTS: 1007 abstracts were identified. Eighteen full texts reported bacterial/fungal co-infection were included. Most studies did not identify or report bacterial/fungal coinfection (85/140;61%). 9/18 (50%) studies reported on COVID-19, 5/18 (28%) SARS-1, 1/18 (6%) MERS, and 3/18 (17%) other coronavirus.For COVID-19, 62/806 (8%) patients were reported as experiencing bacterial/fungal co-infection during hospital admission. Secondary analysis demonstrated wide use of broad-spectrum antibacterials, despite a paucity of evidence for bacterial coinfection. On secondary analysis, 1450/2010 (72%) of patients reported received antimicrobial therapy. No antimicrobial stewardship interventions were described.For non-COVID-19 cases bacterial/fungal co-infection was reported in 89/815 (11%) of patients. Broad-spectrum antibiotic use was reported. CONCLUSIONS: Despite frequent prescription of broad-spectrum empirical antimicrobials in patients with coronavirus associated respiratory infections, there is a paucity of data to support the association with respiratory bacterial/fungal co-infection. Generation of prospective evidence to support development of antimicrobial policy and appropriate stewardship interventions specific for the COVID-19 pandemic are urgently required."],"journal":"Clin Infect Dis","authors":["Rawson, Timothy M","Moore, Luke S P","Zhu, Nina","Ranganathan, Nishanthy","Skolimowska, Keira","Gilchrist, Mark","Satta, Giovanni","Cooke, Graham","Holmes, Alison"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358954","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/cid/ciaa530","keywords":["sars-cov-2","antimicrobial resistance","antimicrobial stewardship"],"locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495313248256,"score":225.88885},{"pmid":32376583,"pmcid":"PMC7167313","title":"[Diagnosis and treatment of an elderly patient with secondary cerebral infarction caused by COVID-19].","text":["[Diagnosis and treatment of an elderly patient with secondary cerebral infarction caused by COVID-19].","We review the experience with the diagnosis and treatment of secondary cerebral infarction in an elderly patient with coronavirus disease 2019 (COVID-19). COVID-19 has rapid disease progression with a high mortality rate in elderly patients, and physicians should be alert to secondary bacterial infection that may result in coagulation dysfunction and cerebral infarction. Early anti-infection therapy, immune regulation and appropriate anticoagulation intervention may help improve the prognosis of the patients.","Nan Fang Yi Ke Da Xue Xue Bao","He, Jin","Cheng, Gong","Xu, Wenwei","Zhang, Lengzhen","Zeng, Zhenhua","32376583"],"abstract":["We review the experience with the diagnosis and treatment of secondary cerebral infarction in an elderly patient with coronavirus disease 2019 (COVID-19). COVID-19 has rapid disease progression with a high mortality rate in elderly patients, and physicians should be alert to secondary bacterial infection that may result in coagulation dysfunction and cerebral infarction. Early anti-infection therapy, immune regulation and appropriate anticoagulation intervention may help improve the prognosis of the patients."],"journal":"Nan Fang Yi Ke Da Xue Xue Bao","authors":["He, Jin","Cheng, Gong","Xu, Wenwei","Zhang, Lengzhen","Zeng, Zhenhua"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376583","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.12122/j.issn.1673-4254.2020.03.10","keywords":["covid-19","cerebral infarction","elderly patients","secondary bacterial infection"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666597097394143232,"score":200.64243},{"pmid":32450346,"title":"Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications.","text":["Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications.","Coronavirus Disease 2019 (COVID-19) has sparked a global pandemic, affecting more than 4 million people worldwide. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause acute lung injury (ALI) and even acute respiratory distress syndrome (ARDS); with a fatality of 7.0 %. Accumulating evidence suggested that the progression of COVID-19 is associated with lymphopenia and excessive inflammation, and a subset of severe cases might exhibit cytokine storm triggered by secondary hemophagocytic lymphohistiocytosis (sHLH). Furthermore, secondary bacterial infection may contribute to the exacerbation of COVID-19. We recommend using both IL-10 and IL-6 as the indicators of cytokine storm, and monitoring the elevation of procalcitonin (PCT) as an alert for initiating antibacterial agents. Understanding the dynamic progression of SARS-CoV-2 infection is crucial to determine an effective treatment strategy to reduce the rising mortality of this global pandemic.","Pharmacol Res","An, Peng-Jiao","Yi, Zhun Zhu","Yang, Li-Ping","32450346"],"abstract":["Coronavirus Disease 2019 (COVID-19) has sparked a global pandemic, affecting more than 4 million people worldwide. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause acute lung injury (ALI) and even acute respiratory distress syndrome (ARDS); with a fatality of 7.0 %. Accumulating evidence suggested that the progression of COVID-19 is associated with lymphopenia and excessive inflammation, and a subset of severe cases might exhibit cytokine storm triggered by secondary hemophagocytic lymphohistiocytosis (sHLH). Furthermore, secondary bacterial infection may contribute to the exacerbation of COVID-19. We recommend using both IL-10 and IL-6 as the indicators of cytokine storm, and monitoring the elevation of procalcitonin (PCT) as an alert for initiating antibacterial agents. Understanding the dynamic progression of SARS-CoV-2 infection is crucial to determine an effective treatment strategy to reduce the rising mortality of this global pandemic."],"journal":"Pharmacol Res","authors":["An, Peng-Jiao","Yi, Zhun Zhu","Yang, Li-Ping"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32450346","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.phrs.2020.104946","keywords":["coronavirus","cytokine storm","immune escape","inflammation","sars-cov-2"],"locations":["cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667785213890002944,"score":160.02153},{"pmid":32378729,"title":"COVID-19 - toward a comprehensive understanding of the disease.","text":["COVID-19 - toward a comprehensive understanding of the disease.","The evidence on the pathophysiology of the novel coronavirus SARS-CoV-2 infection is rapidly growing. Understanding why some patients suffering from COVID-19 are getting so sick, while others are not, has become an informal imperative for researchers and clinicians around the globe. The answer to this question would allow rationalizing the fear surrounding this pandemic. Understanding of the pathophysiology of COVID-19 relies on an understanding of interplaying mechanisms, including SARS-CoV-2 virulence, human immune response, and complex inflammatory reactions with coagulation playing a major role. An interplay with bacterial co-infections, as well as the vascular system and microcirculation affected throughout the body should also be examined. More importantly, a comprehensive understanding of pathological mechanisms of COVID-19 will increase the efficacy of therapy and decrease mortality. Herewith, presented is the current state of knowledge on COVID-19: beginning from the virus, its transmission, and mechanisms of entry into the human body, through the pathological effects on the cellular level, up to immunological reaction, systemic and organ presentation. Last but not least, currently available and possible future therapeutic and diagnostic options are briefly commented on.","Cardiol J","Kowalik, Maciej M","Trzonkowski, Piotr","Lasinska-Kowara, Magdalena","Mital, Andrzej","Smiatacz, Tomasz","Jaguszewski, Milosz","32378729"],"abstract":["The evidence on the pathophysiology of the novel coronavirus SARS-CoV-2 infection is rapidly growing. Understanding why some patients suffering from COVID-19 are getting so sick, while others are not, has become an informal imperative for researchers and clinicians around the globe. The answer to this question would allow rationalizing the fear surrounding this pandemic. Understanding of the pathophysiology of COVID-19 relies on an understanding of interplaying mechanisms, including SARS-CoV-2 virulence, human immune response, and complex inflammatory reactions with coagulation playing a major role. An interplay with bacterial co-infections, as well as the vascular system and microcirculation affected throughout the body should also be examined. More importantly, a comprehensive understanding of pathological mechanisms of COVID-19 will increase the efficacy of therapy and decrease mortality. Herewith, presented is the current state of knowledge on COVID-19: beginning from the virus, its transmission, and mechanisms of entry into the human body, through the pathological effects on the cellular level, up to immunological reaction, systemic and organ presentation. Last but not least, currently available and possible future therapeutic and diagnostic options are briefly commented on."],"journal":"Cardiol J","authors":["Kowalik, Maciej M","Trzonkowski, Piotr","Lasinska-Kowara, Magdalena","Mital, Andrzej","Smiatacz, Tomasz","Jaguszewski, Milosz"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378729","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.5603/CJ.a2020.0065","keywords":["covid-19","sars-cov-2","acute respiratory distress syndrome","coagulation","epidemiology","immunology","therapy"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097325985792,"score":155.80794}]}